Efficacy of a combination of human recombinant erythropoietin + 13‐cis‐retinoic acid and dihydroxylated vitamin D3 to improve moderate to severe anaemia in low/intermediate risk myelodysplastic syndromes

Summary The efficacy of human recombinant erythropoietin (rEPO) in myelodysplastic syndromes (MDS) has generally been best in untransfused patients with ‘refractory anaemia’ according to the World Health Organization (WHO). We treated 63 MDS patients [excluding refractory anaemia with excess blasts,...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 2009-02, Vol.144 (3), p.342-349
Main Authors: Ferrero, Dario, Darbesio, Antonella, Giai, Valentina, Genuardi, Mariella, Dellacasa, Chiara Maria, Sorasio, Roberto, Bertini, Marilena, Boccadoro, Mario
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
anaemia
Anemia - drug therapy
Anemia - etiology
Anemia - mortality
Anemias. Hemoglobinopathies
Biological and medical sciences
Calcitriol - therapeutic use
dihydroxylated cholecalciferole
Diseases of red blood cells
Drug Therapy, Combination
erythropoietin
Erythropoietin - therapeutic use
Female
Hematologic and hematopoietic diseases
Humans
Isotretinoin - therapeutic use
Kaplan-Meier Estimate
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Male
Medical sciences
Middle Aged
myelodysplastic syndromes
Myelodysplastic Syndromes - complications
Myelodysplastic Syndromes - drug therapy
Myelodysplastic Syndromes - mortality
Recombinant Proteins
retinoids
Risk
Survival Rate
Treatment Outcome
Vitamins - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary The efficacy of human recombinant erythropoietin (rEPO) in myelodysplastic syndromes (MDS) has generally been best in untransfused patients with ‘refractory anaemia’ according to the World Health Organization (WHO). We treated 63 MDS patients [excluding refractory anaemia with excess blasts, type 2 (RAEB2)] with a previously tested combination of 13‐cis‐retinoic acid and dihydroxylated vitamin D3 ± 6‐thioguanine in addition to rEPO. Most patients were categorized as refractory cytopenia with multilineage dysplasia and RAEB1, with intermediate 1 International Prognostic Scoring System (IPSS) score; all had Hb
ISSN:0007-1048
1365-2141
DOI:10.1111/j.1365-2141.2008.07465.x